| Mr Steven C Labarbera, MS CCC-SLP | |
|
1199 Pleasant Valley Way, West Orange, NJ 07052-1424 | |
| (973) 243-6956 | |
| Not Available |
| Full Name | Mr Steven C Labarbera |
|---|---|
| Gender | Male |
| Speciality | Speech-language Pathologist |
| Location | 1199 Pleasant Valley Way, West Orange, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124145297 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS00485800 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Steven C Labarbera, MS CCC-SLP 37 Hastings Rd, Old Bridge, NJ 08857-2157 Ph: (732) 679-2421 | Mr Steven C Labarbera, MS CCC-SLP 1199 Pleasant Valley Way, West Orange, NJ 07052-1424 Ph: (973) 243-6956 |
News Archive
Weekly consumption of sports drinks and energy drinks among adolescents is significantly associated with higher consumption of other sugar-sweetened beverages, cigarette smoking, and screen media use, according to a study conducted by researchers from the University of Minnesota and Duke University.
Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.
Nitrous oxide, an effective and inexpensive anesthetic, is safe for surgical patients who have or are at risk for cardiovascular disease, according to results of a large randomized controlled trial being presented at the ANESTHESIOLOGY 2015 annual meeting.
Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
› Verified 7 days ago
Lynn R Reed, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Pleasant Valley Way, West Orange, NJ 07052 Phone: 973-414-4729 | |
Lynn N. Philippe, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1155 Pleasant Valley Way, West Orange, NJ 07052 Phone: 973-731-5100 | |
Miss Giana Nicole Resta, MS CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 520 Prospect Ave, West Orange, NJ 07052 Phone: 973-325-0805 | |
Diane Rose Dearie, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 Executive Dr Ste 10, West Orange, NJ 07052 Phone: 973-896-0422 | |
Velvetspeech Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 59 Main St Ste 340, West Orange, NJ 07052 Phone: 845-480-1261 | |
Leah Melamed Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 39 Moore Ter, West Orange, NJ 07052 Phone: 973-220-9225 |